Supplementary figure S2 from <i>TREX1</i> Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity
Tetsuo Tani(Keio University), David A. Barbie(Dana-Farber Cancer Institute), Jipsa Panchal(Gilead Sciences (United States)), Yingxiao Shi(Dana-Farber Cancer Institute), Caroline G. Fahey(Dana-Farber Cancer Institute), Haritha Mathsyaraja(Fred Hutch Cancer Center), Benjamin Wolf(Gilead Sciences (United States)), Marco Campisi(Dana-Farber Cancer Institute), Ravindra Uppaluri(Dana-Farber Cancer Institute), Jennifer Cain(Gilead Sciences (United States)), Adam Kashishian(Columbia University Irving Medical Center), Shin Saito(Dana-Farber Cancer Institute), Keiichi Ota(Dana-Farber Cancer Institute), Thanh U. Barbie(Brigham and Women's Hospital), Cloud P. Paweletz(Massachusetts General Hospital), Shunsuke Kitajima(Japanese Foundation For Cancer Research), Tran C. Thai(Dana-Farber Cancer Institute), Kei Mizuno(Dana-Farber Cancer Institute), Nobunari Sasaki(Japanese Foundation For Cancer Research), Koji Haratani(Dana-Farber Cancer Institute), Min Wang(Gilead Sciences (United States)), Prafulla C. Gokhale(Harvard University), Navin R. Mahadevan(Brigham and Women's Hospital), Choudhury Fabliha B. Yusuf(Dana-Farber Cancer Institute), Mizuki Homme(Japanese Foundation For Cancer Research), David Liu(University of Louisville), Zehua Li(Dana-Farber Cancer Institute)
Cited by 0
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k